Charles Schwab Investment Management Inc. Makes New $55,000 Investment in TriSalus Life Sciences, Inc. $TLSI

Charles Schwab Investment Management Inc. acquired a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 10,000 shares of the company’s stock, valued at approximately $55,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in shares of TriSalus Life Sciences in the 4th quarter valued at $67,000. Northern Trust Corp grew its position in TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock worth $161,000 after purchasing an additional 5,936 shares during the last quarter. Bank of America Corp DE grew its position in TriSalus Life Sciences by 120,471.6% during the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock worth $894,000 after purchasing an additional 178,298 shares during the last quarter. Bridgeway Capital Management LLC grew its position in TriSalus Life Sciences by 333.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock worth $326,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Connective Capital Management LLC purchased a new position in TriSalus Life Sciences during the 4th quarter worth $140,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Performance

Shares of TriSalus Life Sciences stock opened at $5.15 on Friday. TriSalus Life Sciences, Inc. has a 1 year low of $3.42 and a 1 year high of $5.88. The company has a market capitalization of $256.83 million, a P/E ratio of -4.36 and a beta of 0.49. The company’s fifty day moving average is $4.70 and its two-hundred day moving average is $5.17.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The business had revenue of $11.21 million for the quarter, compared to the consensus estimate of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. As a group, equities analysts expect that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.